Document:

Exhibit 10.33

 

Addendum
Number 4 of the “Up to USD 

150,000.00 Credit Facilites Agreement”

 

 

“Addendum”

 

of

 

 8
January 2021

 

between

 

 

NLS Pharmaceutics Ltd.

Alter Postplatz

6370 Stans

	Switzerland	“Borrower”

 

 

and

 

 

	Ronald Hafner	 	 
	  

	 	“Lender 1”
	 	 	 
	Jürgen Bauer	 	 
	  

	 	“Lender 2”
	 	 	 
	Peter Ödman	 	 
	  

	 	“Lender 3”
	 	 	 
	Michael Stein	 	 
	  

	 	“Lender 4”

 

 

(Lender 1, Lender
2, Lender 3 and Lender 4

the “Lenders”)

 

(Borrower and Lenders
each a “Party”

collectively the “Parties”)

 

 

regarding

current
situation and outstanding amount

 

     

    	Addendum	2/3

    

 

WHEREAS

 

		A.	The Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss law with
its registered seat and principal place of business at Stans (Company Number CHE-447.067.367). The Company has a share capital
of CHF 139’200.00, divided into 6’960’000 registered shares with a nominal value of CHF 0.02 each, which
have been fully paid in.

 

		B.	The Lenders and the Borrower (formerly NLS Pharma AG) entered into the “Up to USD 150,000.00
Credit Facilities Agreement” dated 31 August 2015, as amended on 16 September 2019, on 3 February and in October 2020 (“Agreement”).
The Lenders agreed to make available to the Borrower credit facilities in the aggregate amount of USD 150,000.00 (“Total
Credit Facility Amount”).

 

		C.	The Lenders granted to the Borrower the Total Credit Facility Amount under the Agreement.

 

		D.	According to section 6.1 of the Agreement, the loans under Total Credit Facility Amount shall bear
regular interest at the rate of 0% per annum, calculated from (and including) the day of its drawdown to (and including) the Maturity
Date (or the date of its earlier repayment).

 

		E.	According to section 6.2 of the Agreement, default interest rate of 5% per annum shall apply, in
case the Borrower does not make any payment on the due date as foreseen in the Agreement.

 

		F.	The maturity date for the repayment of the Total Credit Facility Amount together with the accrued
interest was set at 31 December 2020 (“Maturity Date”).

 

NOW,
THEREFORE, the Parties agree as follows:

 

Any capitalized terms, if not defined otherwise
in this Addendum, shall have the meaning as set forth in the Agreement.

 

		1.	Open Amount

 

The Parties hereby confirm
that the Total Credit Facility Amount has not been repaid to the Lenders by the Borrower.

 

		2.	Extension Maturity Date

 

The Maturity Date as set forth
in section 5 of the Agreement shall be extended from 31 December 2020 to 31 March 2021.

 

		3.	Governing Law and Jurisdiction

 

This Addendum shall be governed
by and construed in accordance with the substantive laws of Switzerland, without reference to principles of conflict of laws or
choice of laws.

 

All disputes arising out of
or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment and termination, shall
be resolved by the ordinary courts in Stans (NW), Switzerland.

 

 

[Signature page to follow]

 

     

    	Addendum	3/3

    

 

Borrower

NLS Pharmaceutics Ltd.

 

	/s/ Ronald Hafner	 	/s/ Alexander Zwyer
	Ronald Hafner

        Chairman of
        the Board
	 	Alexander Zwyer

        Chief Executive
        Officer

	 	 	 
	 	 	 

Lenders

 

	/s/ Ronald Hafner	 	/s/ Jürgen Bauer
	Ronald Hafner
	 	Jürgen
        Bauer

	 	 	 
	/s/ Peter Ödman 	 	/s/ Michael Stein 
	Peter Ödman
	 	Michael SteinExhibit 10.34

 

Addendum
Number 4 of the “Up to USD 

7,100,000 Credit Facilites Agreement”

 

 

“Addendum”

 

of

 

8 January 2021

 

between

 

 

	NLS
    Pharmaceutics Ltd.	 	 
	Alter
    Postplatz	 	 
	6370
    Stans	 	 
	Switzerland	 	“Borrower”
	 	 	 
	 	 	 
	 	and	 
	 	 	 
	 	 	 
	Ronald
    Hafner	 	 
	  

	 	“Lender 1”
	 	 	 
	Jürgen Bauer	 	 
	 	 	“Lender
    2”
	 

 	 	 
	Peter Ödman	 	 
	 

 

	 	“Lender
    3”
	 	 	 
	Michael Stein	 	 
	  

	 	“Lender
    4”
	 	 	 

 

(Lender 1, Lender
2, Lender 3 and Lender 4

the ʺLendersʺ)

 

(Borrower and Lenders
each a ʺPartyʺ

collectively the ʺPartiesʺ)

 

 

regarding

current situation and outstanding
amount

     

    	Addendum	2/5

    

 

WHEREAS

 

		A.	The Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss law with
its registered seat and principal place of business at Stans (Company Number CHE-447.067.367). The Company has a share capital
of CHF 139’200.00, divided into 6’960’000 registered shares with a nominal value of CHF 0.02 each, which have been fully paid
in.

 

		B.	The Lenders and the Borrower (formerly NLS Pharma AG) entered into the “Up to USD 7,100,000
Credit Facilities Agreement” dated 31 August 2015, as amended on 16 September 2019, on 3 February 2020 and in October 2020
(“Agreement”). The Lenders agreed to make available to the Borrower credit facilities in the aggregate amount
of USD 7,100,000.00 (“Total Credit Facility Amount”).

 

		C.	The Lenders granted to the Borrower the Total Credit Facility Amount under the Agreement.

 

		D.	According to section 6.1 of the Agreement only the loans under Credit Facility D shall bear interest
at the rate of 10% per annum, calculated from (and including) the day of its drawdown to (and including) the Maturity Date (or
the date of its earlier repayment).

 

		E.	With the capital increase dated 19 July 2018 (“Capital Increase I”) part of the
Total Credit Facility Amount in the amount of USD 3,418,519.00 (“Converted Amount I”) was converted and setoff
against 52 registered shares at a nominal amount of CHF 100.00. The Lenders each received thirteen (13) registered shares at an
issue price of USD 65,740.75 per share, as stated in the subscription form signed by each Lender. Part of the Converted Amount
I was the total Credit Facility D amount (USD 500,000.00). After the capital increase dated 19 July 2018 an open amount of USD
3,681,481.00 remained (“Open Amount”).

 

		F.	With the capital increase dated 12 March 2019 (“Capital Increase II”) the Open
Amount was converted and setoff against 56 registered shares at an issue price of USD 65,740.75 per share, as stated in the subscription
form signed by each Lender. The Lenders each received fourteen (14) registered shares.

 

		G.	With the Capital Increase I and the Capital Increase II the Total Credit Facility Amount was converted
and setoff.

 

		H.	The maturity date for the repayment of the Total Credit Facility Amount together with the accrued
interest was set at 31 December 2020 (“Maturity Date”).

 

NOW,
THEREFORE, the Parties agree as follows:

 

Any capitalized terms, if not defined otherwise
in this Addendum, shall have the meaning as set forth in the Agreement.

 

		1.	Open Amount

 

The Parties hereby confirm
that the Total Credit Facility Amount was converted and setoff in accordance with the Agreement. Therefore, no open amount remains
with regard to the Total Credit Facility Amount.

 

		2.	Conversion of Credit Facility D and Interest

 

The Parties hereby agree and
confirm that the total amount of the Credit Facility D was converted with the Capital Increase I.

 

     

    	Addendum	3/5

    

 

According to the document from
GHM Partners (Annex 1), the accrued interest shall consequently be calculated from 25 November 2016 until and including
the date of the Capital Increase I. The accrued interest as of the date hereof therefore equals USD 85’737.00 (“Open Interest
Amount”).

 

		3.	Extension Maturity Date

 

The Maturity Date for the Open
Interest Amount shall be extended until 31 March 2021.

 

		4.	Governing Law and Jurisdiction

 

This Addendum shall be governed
by and construed in accordance with the substantive laws of Switzerland, without reference to principles of conflict of laws or
choice of laws.

 

All disputes arising out of
or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment and termination, shall
be resolved by the ordinary courts in Stans (NW), Switzerland.

 

 

[Signature page to follow]

 

     

    	Addendum	4/5

    

 

Borrower

NLS Pharmaceutics Ltd.

 

	/s/ Ronald Hafner	 	/s/ Alexander Zwyer
	Ronald
    Hafner	 	Alexander
    Zwyer
	Chairman
    of the Board	 	Chief
    Executive Officer
	 	 	 
	 	 	 
	Lenders	 	 
	 	 	 
	/s/ Ronald Hafner	 	/s/ Jürgen Bauer
	Ronald
    Hafner	 	Jürgen
    Bauer
	 	 	 
	/s/ Peter Ödman	 	/s/ Michael Stein
	Peter
    Ödman	 	Michael
    Stein

 

 

Annex 1: Excel sheet from GHM Partners.

 

     

    	Addendum	5/5

    

 

Annex 1

 

Excel sheet from GHM Partners

 

	Investors A - Credit Facility (part II of USD 7.1m)	 	 	2018	 	 	 	18.03.2019	 	 	 	31.12.2019	 	 	 	30.06.2020	 
	ex NLS-1	 	 	USD	 	 	 	USD	 	 	 	USD	 	 	 	USD	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Credit facility Investors A	 	 	3’681’481.00	 	 	 	3’681’481.00	 	 	 	-	 	 	 	-	 
	Interest rate 0 %	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Debt to equity swap 18.3.2019	 	 	 	 	 	 	-3’681’481.00	 	 	 	 	 	 	 	 	 
	Total Credit Facility	 	 	3’681’481.00	 	 	 	-	 	 	 	-	 	 	 	-	 
	Interest 2016-2018 (of USD 500k)	 	 	85’737.00	 	 	 	85’737.00	 	 	 	85’737.00	 	 	 	85’737.00	 
	Total Credit Facility incl. Interest *	 	 	3’767’218.00	 	 	 	85’737.00	 	 	 	85’737.00	 	 	 	85’737.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

		*	Maturity date is September 30, 2020Exhibit 10.35

 

NLS Pharmaceutics Ltd.

Alter Postplatz 2

CH-6370 Stans

 

8
January 2021

 

Addendum
Number 4 to Convertible Promissory Note (“Addendum”)

 

Magnetic
Rock Investment AG, a Swiss stock corporation with its registered office at ________________, Switzerland, and company no.
CHE-184.662.704 (the “Lender”), granted to NLS Pharmaceutics Ltd. (formerly NLS-1 Pharma AG), a Swiss
stock corporation with its registered office at Alter Postplatz 2, 6370 Stans, Switzerland, and company no. CHE-447.067.367 (the
“Borrower”), based on the promissory note dated 18 January 2019, as amended on 16 September 2019, in January
2020 and on 3 October 2020 (the “Promissory Note”) the principal sum of CHF 550,000.00 (the “Principal
Amount”), together with interest at 10.0% p.a. (the “Interest”) thereon accruing on and from the
date of payment until the entire Principal Amount is repaid (the Interest and the Principal Amount hereinafter jointly referred
to as the “Loan”). The Interest shall be calculated based on the exact number of days in relation to a year
of 360 days (actual/360), compounded annually.

 

For
the sake of clarity, CHF 500,000.00 of the Principle Amount (“Payment A”) was paid to the Borrower on 31 August
2018 (the “Date of Payment A”) and CHF 50,000.00 of the Principle Amount (“Payment B”) was
paid to the Borrower on 18 December 2018 (the “Date of Payment B”).

 

On
12 March 2019 CHF 526,979.84 of the Principal Amount was settled by conversion into equity (the “Conversion Amount”),
whereas the Lender received eight (8) registered shares at an issue price of CHF 65,872.48 (the “Conversion”).
The Conversion Amount consists of the full amount of Payment B and of CHF 476,979.84 from Payment A. As a result of the Conversion,
an outstanding amount of CHF 23,020.16 with regard to Payment A (the “Open Amount Payment A”) remains open.

 

The
following is a statement of the amended terms and conditions of the Promissory Note:

 

	1
        – Extension Maturity Date

         
	 	According
        to section 2 of the Promissory Note, the Maturity Date and therefore the repayment of the Loan was agreed to take place
        no later than 31 December 2020.

         

        According
        to section 2 of the Promissory Note, the Lender may unilaterally extend the repayment term and set a new Maturity Date.

         

        The
Lender hereby extends the Maturity Date of the Loan, replacing the existing Maturity Date, until 31 March 2021 and, thus, the
Loan shall be due for repayment no later than 31 March 2021. The Borrower hereby acknowledges and agrees with the extension. References
to the Maturity Date in the Promissory Note shall be to 31 March 2021.

	 	 	 
	2
    - Governing Law	 	This
Addendum shall be governed by and construed in accordance with the substantive laws of Switzerland, without reference to principles
of conflict of laws or choice of laws.

	 	 	 
	3
    – Jurisdiction	 	All
disputes arising out of or in connection with this Addendum, including disputes regarding its conclusion, validity, binding effect,
amendment, breach, termination or rescission shall be subject to the exclusive jurisdiction of the ordinary courts of Stans (NW). 

 

 

[signature
page to follow]

 

     1

     

    

 

The
Lender

Magnetic
Rock Investment

 

	/s/
    Ronald Hafner	 	 
	Ronald
    Hafner	 	 
	Chairman
    of the Board of Directors	 	 
	 	 	 
	 	 	 
	The
    Borrower	 	 
	NLS
    Pharmaceutics Ltd.	 	 
	 	 	 
	/s/
    Alexander Zwyer	 	/s/
    Ronald Hafner
	Alexander
    Zwyer	 	Ronald
    Hafner
	Chief
    Executive Officer	 	Chairman
    of the Board of Directors

 

     2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]